Menu
ncarol.com
  • Home
  • Business
  • Health
  • Real Estate
  • Non-profit
  • Arts
  • Education
  • Technology
  • Books
ncarol.com

Sydney Brachytherapy Group is the first private non-melanoma skin cancer clinic in Sydney to offer OncoBeta's Rhenium-SCT
ncarol.com/10192926

Trending...
  • Pyro Marketing Opens New Digital Marketing Company to Power Growth for Fitness and Ecommerce Brands
  • LIB and Nidec Rejoin Forces for Giant TH-0098 Temperature Humidity Test Chamber
  • Adostics & Genmega Announce the Introduction of A-POD
Dr Joseph Grace at Sydney Brachytherapy Group Rhenium-SCT Personalised Treatment On Temple OncoBeta GmbH
SYDNEY - ncarol.com -- OncoBeta® GmbH, a medical device company specialising in innovative epidermal radioisotope therapies, today announces the Sydney Brachytherapy Group is the first private clinic in NSW performing Rhenium-SCT® for patients with non-melanoma skin cancers (NMSCs).

Rhenium-SCT® is an advanced radionuclide therapy technology that offers a non-invasive, predominantly single-session treatment with improved cosmetic outcomes for patients suffering from Basal Cell and Squamous Cell Carcinomas (BCCs and SCCs). With the global incidence rates of NMSCs increasing, and more than 7.7 million cases of NMSC being recorded each year1,2, this technology offers patients a new treatment option.

Dr Joseph Gracé, Medical Director of Sydney Brachytherapy Group says, "NMSC is a significant health concern here in Australia (especially for those with Fitzpatrick Skin Types I–III), and we are excited to offer Rhenium-SCT® to our patients with NMSC. The non-invasive nature of this treatment, especially for tumours in hard to reach anatomical locations, is one of the main reasons for using Rhenium-SCT®."

Standard treatments for NMSCs typically require surgery, whereas Rhenium-SCT® uses a non-invasive paste containing ß-emitting particles which are applied directly to a lesion to target cancer cells.3

"The key difference to other therapies is that the Rhenium-SCT® is more precise, allowing the physician to administer treatment locally without damaging surrounding tissue. Patients with difficult anatomic localisations of a tumour, such as ear, nose or anywhere on the face,  and those with larger lesions problematic for plastic surgery may benefit from this non-invasive solution, which provides preferrable aesthetic outcomes." adds Dr Gracé.

Shannon D. Brown III, CEO and Managing Director at OncoBeta, says, "This is a significant milestone in the international availability of  Rhenium-SCT® for patients in Australia,  and yet another step in having Rhenium-SCT® offered  in the suite of treatments available to patients suffering with NMSCs."

Sydney Brachytherapy Group is now taking patient referrals from dermatology and skin cancer specialists – for more information please visit: www.sydneybrachytherapy.com or for information about OncoBeta and Rhenium-SCT please visit:  www.oncobeta.com

More on ncarol.com
  • Duke Energy announces dividend payments to shareholders
  • $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
  • Financial Educator Nadia Vanderhall Featured On GMA To Share Real-Life Budgeting Insights
  • Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
  • $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group

About the Rhenium-SCT® (Skin Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.2 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.6
The Rhenium-SCT® is a painless*, single session†, non-invasive therapy that provides aesthetic results, even in cases otherwise considered difficult to treat.3-5 The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalised therapy that is only applied to the area needed to treat without affecting the healthy tissue. The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patient's skin and the application is safe and simple for the applying physician. Most cases of NMSCs (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT in one single session.†5 Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.5

About OncoBeta®
OncoBeta®, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.
Find out more about the Rhenium-SCT® at www.oncobeta.com
Follow us on social media:
LinkedIn: www.linkedin.com/company/oncobeta-gmbh/
Facebook: www.facebook.com/oncobeta/

More on ncarol.com
  • New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
  • SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
  • TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas
  • Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
  • KCON LA 2025, 106.3 RAIN FM 'Take Over' Special Event

Instagram: www.instagram.com/oncobeta_gmbh/

About The Sydney Brachytherapy Group
The Sydney Brachytherapy Group is a multispecialist, multidisciplinary service of healthcare provided at the interventional suites at the North Shore Medical Group. Medical Director, Dr. Joseph Gracé chairs the medical advisory committee of Registered specialist medical practitioners (Visiting Medical Officers or VMO's), who are accredited by that committee. The VMO specialists include Nuclear Physicians, Dermatologists, Plastic Surgeons, Skin Cancer Surgeons and Oncologists. Sydney Brachytherapy is also participating in research and development and contributes to the International OncoBeta Skin Cancer Registry.
Phone: 02 8061 4048
Email: webcontact@sydneybrachytherapy.com
Website: www.sydneybrachytherapy.com
Address: Suite 304, 156-158 Pacific Highway
ST LEONARDS NSW 2065 Australia.

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
*No reported pain3,4
†
Complete tumour regression in 98.5% of lesions treated5

References
  1. Global Burden of Disease Cancer Collaboration, et al. JAMA Oncol. 2019;5(12):1749-1768.
  2. Ciążyńska M, et al. Sci Rep. 2021;11(1):4337.
  3. Cipriani C, et al. J Dermatolog Treat. 2020; Jul 22:1-7.
  4. Sedda AF, et al. Clin Exp Dermatol. 2008;33(6):745-749.
  5. Cipriani C, Sedda AF. Therapeutic Nuclear Medicine, editor Baum RP; New York: Springer, 2014.
  6. Cancer.net. Skin Cancer (Non-Melanoma): Risk Factors and Prevention. October 2020. https://www.cancer.net/cancer-types/skin-cancer-non-melanoma/risk-factors-and-prevention (accessed March 2022).


Contact
Jane Morey
***@moreymedia.com.au


Source: OncoBeta GmbH
Filed Under: Health

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
  • Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
  • Colbert Packaging Announces WBENC Recognition
  • DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
  • Hilton Charlotte Uptown Hosts First-Ever Premium Tailgate Experience
  • Assent Expands Executive Team to Accelerate Global Growth & Innovation
  • The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
  • Vinnetwork Unveils Decentralized AI Platform with Vinnetwork(VIN) Token to Challenge Tech Giants' Data Monopoly
  • Centennial Flyers to Become Colorado's First Launch Customer for All-Electric B23 Energic Aircraft
  • Pyro Marketing Opens New Digital Marketing Company to Power Growth for Fitness and Ecommerce Brands
  • Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
  • $14M Expansion Deal with Famed David Lloyd Highlights Rebrand of Sports, Entertainment and Gaming Innovation by AI Driven, Online Fan Engagement Co
  • Marvelous Mouse Talk Named One of the Top 100 Disney Podcasts by MillionPodcasts
  • Heartfelt Dreams Foundation Launches Campaign to Build CHD Hospital
  • Radarsign Tackles Intersection Safety with Launch of Grid-Free Solar LED Stop Sign
  • Needing a windshield replacement in North Carolina?
  • Miami Real Estate Agent Drastically Increases Interest In Homes
  • Adostics & Genmega Announce the Introduction of A-POD
  • New Bible Study Unpacks Jesus' Prophecy on Temple Destruction and His Return
  • LIB and Nidec Rejoin Forces for Giant TH-0098 Temperature Humidity Test Chamber
_catLbl0 _catLbl1

Popular on ncarol.com

  • Jeopardy!'s Ken Jennings Headlines National Mensa Event
  • A Family Affair: Abernethy Laurels Hosts a Wedding with Heart
  • OPRAH.COM Featured Award-Winning Novel AS FAR AS YOU GO BEFORE YOU HAVE TO COME BACK now Available as Audiobook
  • Mensa Foundation Prize Awarded to Neuroscientist-Pianist
  • KeysCaribbean Vacation Home Rentals Offers Last-Minute Booking Discount of 15 Percent
  • Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
  • Investor Spotlight: Cycurion, Inc. (N A S D A Q: CYCU) Secures $69M in Contracts Amid Surging Demand for AI-Powered Cybersecurity Solutions
  • databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research
  • Dr. Jacqueline West Honored as Best Dentist in JAX by Folio Weekly
  • IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement

Similar on ncarol.com

  • Fastest Growing Staffings Firms
  • Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
  • Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
  • The Citizens Commission on Human Rights Annual Purple Heart Day Event will be Hosted at the Historic Fort Harrison
  • Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science
  • The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
  • Josh and Heidi Follow Up the Much Anticipated and Successful Launch of the "Spreading the Good BUZZ" Podcast with a Personal Request
  • Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
  • Colbert Packaging Announces WBENC Recognition
  • Pyro Marketing Opens New Digital Marketing Company to Power Growth for Fitness and Ecommerce Brands
Copyright © 2025 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute